ProKidney Corp. (NASDAQ:PROK) has released positive interim results for its REGEN-007 Phase 2 trial.

The study evaluates its renal autologous cell therapy, rilparencel.

In Group 1, patients with at least a year of follow-up post-treatment demonstrated stabilized kidney function for 18 months.

The average change in eGFR from baseline was -1.3 ml/min/1.73m².

Additionally, no serious adverse events related to rilparencel were observed.

Bruce Culleton, CEO of ProKidney, remarked on the significance of these findings, stating, "These are critically important operational milestones for ProKidney. The interim results from REGEN-007 are promising and reveal the potential of rilparencel to preserve kidney function in patients with moderate to severe CKD."

Meanwhile, ProKidney also announced the resumption of its manufacturing activities and the continuation of its Phase 3 trials, PROACT 1 and PROACT 2.

The company expects to begin enrolling new patients in these trials soon.